Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News GlaxoSmithKline’s ViiV Healthcare venture earns EU approval for HIV drug

GlaxoSmithKline’s ViiV Healthcare venture earns EU approval for HIV drug

4th September 2014

GlaxoSmithKline has announced that ViiV Healthcare, its joint venture with Pfizer, has been granted European regulatory approval for a convenient new HIV therapy.

The European Commission has granted marketing authorisation for Triumeq, a new once-daily single-pill regimen for the treatment of HIV-positive adults and adolescents aged 12 years and older and weighing at least 40 kg.

Triumeq combines the integrase strand transfer inhibitor dolutegravir with the nucleoside reverse transcriptase inhibitors abacavir and lamivudine. It has demonstrated its safety and efficacy in a number of phase III clinical trials.

Before treatment with this product, prospective patients should be screened for the presence of the HLA-B*5701 allele, as carriers of this genetic marker are known to be at high risk of a hypersensitivity reaction to abacavir.

Dr Dominique Limet, chief executive officer at ViiV Healthcare, said: "As a company that focuses 100 percent on HIV, our commitment is to continue to deliver new options for care and treatment for people living with HIV."

This comes after ViiV Healthcare received EU approval for another HIV drug, Tivicay, earlier this year.ADNFCR-8000103-ID-801746608-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.